Answer
In efavirenz/emtricitabine/tenofovir disoproxil Glenmark, efavirenz inhibits HIV-1 reverse transcriptase non-competitively, while emtricitabine and tenofovir (formed from tenofovir disoproxil) undergo cellular phosphorylation to emtricitabine triphosphate and tenofovir diphosphate, which competitively inhibit the enzyme, terminating DNA chains.
Sources for this answer
- Efavirenz/Emtricitabine/Tenofovir disoproxil Glenmark 600 mg/ 200 mg/245 mg film-coated tabletsGlenmark Pharmaceuticals Europe Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 5Document updated
Sources checked